Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

8.18
-0.0900-1.09%
Post-market: 8.250.0700+0.86%19:51 EDT
Volume:4.16M
Turnover:34.12M
Market Cap:1.78B
PE:-5.76
High:8.42
Open:8.26
Low:8.04
Close:8.27
52wk High:16.44
52wk Low:5.80
Shares:217.69M
Float Shares:191.00M
Volume Ratio:1.31
T/O Rate:2.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4203
EPS(LYR):-1.4203
ROE:-54.85%
ROA:-26.66%
PB:2.72
PE(LYR):-5.76

Loading ...

U.S. Small Caps Close Mixed As ZIM Integrated Shipping Leads, Ocular Therapeutix Lags

Dow Jones
·
Feb 18

Ocular Therapeutix selloff brings attractive entry point, says Citizens

TIPRANKS
·
Feb 18

Ocular Therapeutix Down Over 25%, on Pace for Largest Percent Decrease Since October 2021 -- Data Talk

Dow Jones
·
Feb 18

Analysts Offer Insights on Healthcare Companies: Cybin (HELP) and Ocular Therapeutix (OCUL)

TIPRANKS
·
Feb 18

Ocular Therapeutix: SOL-1 Data Validate Axpaxli and Overdone Sell-Off Supports Buy Rating

TIPRANKS
·
Feb 17

Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff

TIPRANKS
·
Feb 17

Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes

Benzinga_recent_news
·
Feb 17

Stock Track | Ocular Therapeutix Plunges 22.31% Pre-market Despite Positive Phase 3 Trial Results for Wet AMD Drug

Stock Track
·
Feb 17

Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint

TIPRANKS
·
Feb 17

Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron's Eylea

Reuters
·
Feb 17

Ocular Therapeutix Shares Down 27% Premarket After Co Reports Late‑Stage Eye‑Disease Trial Data

THOMSON REUTERS
·
Feb 17

Ocular Therapeutix Reports Positive Phase 3 Results for AXPAXLI in Wet AMD

Reuters
·
Feb 17

Ocular Therapeutix: Complementary Sol-R Phase 3 Non-Inferiority Trial of Axpaxli in Wet Amd to Continue as Planned, Topline Data Expected Q1 2027

THOMSON REUTERS
·
Feb 17

Ocular Therapeutix Inc - Plans to Submit Nda Based on Sol-1 Data

THOMSON REUTERS
·
Feb 17

Ocular Therapeutix Inc - Axpaxli Well-Tolerated With No Ocular Saes in Sol-1

THOMSON REUTERS
·
Feb 17

Ocular Therapeutix: Reports Positive Results From Sol-1 Phase 3 Superiority Trial in Wet Amd

THOMSON REUTERS
·
Feb 17

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

Reuters
·
Feb 17

Ocular Therapeutix: Axpaxli Was Generally Well-Tolerated in Sol-1 With No Treatment-Related Ocular Saes

THOMSON REUTERS
·
Feb 17

Ocular Therapeutix: at Weeks 36 & 52, Subjects in Axpaxli Arm Demonstrated Sustained Csft Control Compared to Subjects in Aflibercept Arm

THOMSON REUTERS
·
Feb 17

Ocular Therapeutix: Axpaxli Met Its Week 52 Durability Assessment With High Statistical Significance

THOMSON REUTERS
·
Feb 17